Possibilities and Predictions...., page-31

Hey ahjay ,thanx for the article m8,lots of info on the subject.In other readings on the subject ,I have done,they explain that the process takes on average about 6 months to complete.The company stated that they had commenced this process in the 3rd quarter ,making the process possibly being completed by the first quarter 2019.Once the GMP ,goods manufacturing production ,is completed,you’d imagine the company would want to progress with the phase 1 trial commencement.Which brings us to the point on how that may play out ,is the company in the position to initially go it alone ,and pay for the trial roll out ,or are they currently in negotiations with a party tio negotiate a deal ,or have they already negotiated a deal and it’s being finalised.The following statement by Voight ,gives me confidence something may be just around the corner,

Immutep CEO, Mr Marc Voigt commented “IMP761 is a first-in-class product candidate that has the potential to address the underlying cause of most autoimmune diseases. As leaders in the LAG-3 space, we are very excited to be moving forward with this innovative program and I believe Immutep is well positioned to translate the science and pre-clinical evidence we are seeing for IMP761 into a revolutionary therapeutic approach for autoimmune diseases.”
We know they have the data ,they have stated it’s encouraging .